CD28, costimulator or agonist receptor?

被引：19
|
作者：
Margulies, DH [1 ]
机构：
[1] NIAID, Mol Biol Sect, Immunol Lab, NIH,DHHS, Bethesda, MD 20892 USA
来源：
JOURNAL OF EXPERIMENTAL MEDICINE | 2003年 / 197卷 / 08期
关键词：
D O I：
10.1084/jem.20030303
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：949 / 953
页数：5
相关论文
共 50 条
  • [21] Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis
    Wilson, Leslie
    Lewis, Katherine E.
    Evans, Lawrence S.
    Dillon, Stacey R.
    Pepple, Kathryn L.
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2023, 12 (03):
  • [22] Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
    Davar, Diwakar
    Moser, Justin C.
    Millward, Michael
    Voskoboynik, Mark
    Lakhani, Nehal J.
    Sanborn, Rachel E.
    Grewal, Jaspreet Singh
    Narayan, Ajita
    Sznol, Mario
    Dillon, Stacey R.
    Schieber, Keren
    Zayed, Hany
    Dela Cruz, Christine Marie
    Perez, Graciela Noemi
    Peng, Stanford L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice
    Li, Jun
    Semple, Kenrick
    Suh, Woong-Kyung
    Liu, Chen
    Chen, Fangping
    Blazar, Bruce R.
    Yu, Xue-Zhong
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (07) : 962 - 969
  • [24] Mitochondrial Priming by CD28
    Geltink, Ramon I. Klein
    O'Sullivan, David
    Corrado, Mauro
    Bremser, Anna
    Buck, Michael D.
    Buescher, Joerg M.
    Firat, Elke
    Zhu, Xuekai
    Niedermann, Gabriele
    Caputa, George
    Kelly, Beth
    Warthorst, Ursula
    Rensing-Ehl, Anne
    Kyle, Ryan L.
    Vandersarren, Lana
    Curtis, Jonathan D.
    Patterson, Annette E.
    Lawless, Simon
    Grzes, Katarzyna
    Qiu, Jing
    Sanin, David E.
    Kretz, Oliver
    Huber, Tobias B.
    Janssens, Sophie
    Lambrecht, Bart N.
    Rambold, Angelika S.
    Pearce, Edward J.
    Pearce, Erika L.
    CELL, 2017, 171 (02) : 385 - +
  • [25] SIGNALING INTERMEDIATES OF CD28
    BEN-NERIAH, Y
    ALKALAY, I
    YARON, A
    HATZUBAI, A
    JUNG, S
    RESEARCH IN IMMUNOLOGY, 1995, 146 (03): : 154 - 158
  • [26] CD28: A signalling perspective
    Ward, SG
    BIOCHEMICAL JOURNAL, 1996, 318 : 361 - 377
  • [27] Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines
    Gilfillan, MC
    Noel, PJ
    Podack, ER
    Reiner, SL
    Thompson, CB
    JOURNAL OF IMMUNOLOGY, 1998, 160 (05): : 2180 - 2187
  • [28] Distinct CD28 signaling requirements determine the alternative fates of thymic agonist selection
    Watanabe, Masashi
    Alkhaleel, Farrah
    Hodes, Richard J.
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [29] ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, enhances the activity of multiple standard of care modalities
    Lewis, Katherine
    Maurer, Mark
    Mudri, Sherri
    Susmilch, Kayla
    Ahmed-Qadri, Fariha
    Gudgeon, Chelsea
    Levin, Steven
    Wolfson, Martin
    Dillon, Stacey
    Swiderek, Kristine
    Peng, Stanford
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Inducible T-cell costimulator (ICOS) and CD28 polymorphisms possibly play a role in the pathogenesis of chronic autoreactive urticaria
    Brzoza, Z.
    Grzeszczak, W.
    Trautsolt, W.
    Moczulski, D.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2017, 42 (08) : 863 - 867
12345